J
Jabez Biosciences develops cancer therapeutics based on a "3-S" framework: Seamless, Scalable, and Synergistic. This approach focuses on creating well-tolerated, orally available small molecules that integrate easily with existing standard therapies. The company is advancing its lead candidate, an oral DHODH inhibitor, through Phase 1 clinical trials to demonstrate improved patient outcomes without added complexity.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Jabez Biosciences develops cancer therapeutics based on a "3-S" framework: Seamless, Scalable, and Synergistic. This approach focuses on creating well-tolerated, orally available small molecules that integrate easily with existing standard therapies. The company is advancing its lead candidate, JBZ-001, an oral DHODH inhibitor currently in Phase 1 clinical trials.